Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
Havva KocayigitKezban Özmen SünerYakup TomakGurkan DemirSelcuk YaylacıHamad DheirErtugrul GuçluAli Fuat ErdemPublished in: Journal of clinical pharmacy and therapeutics (2020)
The length of hospital stay was significantly lower in the FVP group compared to the LPV/r group among patients who were discharged from the ICU. Although the analysis was done with a limited number of patients and the observed difference in mortality rate is of some concern, FVP treatment may be more beneficial than LPV/r in terms of effective use in the ICU.
Keyphrases
- end stage renal disease
- intensive care unit
- chronic kidney disease
- ejection fraction
- newly diagnosed
- mechanical ventilation
- healthcare
- emergency department
- prognostic factors
- peritoneal dialysis
- cardiovascular events
- cardiovascular disease
- patient reported outcomes
- coronary artery disease
- adverse drug
- patient reported
- acute care